Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SIDI Program Will Standardize Ingredient Protocol – Supplement Trade Groups

This article was originally published in The Tan Sheet

Executive Summary

A voluntary protocol could prompt "a major paradigm shift for many in the [dietary supplement] industry by moving away from unique individualized questionnaires towards standardized documentation and information exchange," trade groups say

You may also be interested in...



PCA Indictments Send Warnings On Vendor Qualification, Responsibility

The Justice Department’s decision to indict four former officials of Peanut Corporation of America for distributing and covering up information related to tainted peanuts illustrates the need for supplement makers to qualify their vendors, industry leaders say.

PCA Indictments Send Warnings On Vendor Qualification, Responsibility

The Justice Department’s decision to indict four former officials of Peanut Corporation of America for distributing and covering up information related to tainted peanuts illustrates the need for supplement makers to qualify their vendors, industry leaders say.

Supplier Qualification Guideline Touts Flexibility, Defers Best Practices

The Standardized Information on Dietary Ingredients Work Group publishes a guide to help supplement firms qualify ingredient suppliers under FDA good manufacturing practices. But with only three out of five major industry associations involved, not everyone is on board with the SIDI efforts.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel